Novartis published clinical trial results about KAE609, KAE609 was tested in 12 adult patients with uncomplicated malaria and showed a median parasite clearance time of 12 hours, including in patients with resistant infections. The result showed that KAE609 cleared the parasite rapidly in Plasmodium falciparum (P. falciparum) and Plasmodium vivax (P. vivax) uncomplicated malaria patients. The clinical result s were published in the New England Journal of Medicine

At present, Novartis currently has two drug candidates in development. Both KAE609 and KAF156 are new classes of anti-malarial compounds that treat malaria in different ways from current therapies, important to combat emerging drug resistance. Novartis has also identified PI4K as a new drug target with potential to prevent, block and treat malaria.

Malaria is a life-threatening disease primarily caused by parasites (P. falciparum and P. vivax) transmitted to people through the bites of infected Anopheles mosquitoes. Each year it kills more than 600,000 people, most of them African children. KAE609 is a potential game-changing therapy in the fight against malaria, which is the first compound in the spiroindolone class of treatment works through a novel mechanism of action that involves inhibition of a P-type cation-transporter ATPase4 (PfATP4), which regulates sodium concentration in the parasite. Because KAE609 also appears to be effective against the sexual forms of the parasite, it could potentially help prevent disease transmission. Novartis has given KAE609 priority project status because of its unique potential of administering it as a single-dose combination therapy

More information please pay attention to the following address

http://www.malaria.novartis.com/newsroom/press-releases/2014-07-kae609.shtml